The now completed VISIONARY study marks another milestone in Otsuka’s rolling sBLA submission.

In a milestone for IgA nephropathy, Otsuka’s Voyxact has shown for the first time in a phase 3 trial that a drug can stabilize patients’ kidney function decline to the normal rate seen in healthy ...

This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether VOYXACT slows kidney function decline over the long-term in patients with ...

“For patients with IgA nephropathy, slowing the loss of kidney function is essential to improve long-term outcomes, including the likelihood of kidney failure and the need for dialysis or transplant,” ...

The FDA has approved MediBeacon®'s TGFR system for noninvasive kidney function assessment, targeting both normal and impaired renal patients. INNOVATE Corp. announced the FDA approval of the ...

Please provide your email address to receive an email when new articles are posted on . The paper provides a race-free equation to estimate kidney filtration in adults with stable kidney function. It ...

Having a cystatin C-based eGFR value at least 30% lower than creatinine-based eGFR is associated with increased risks of early death, cardiovascular events, and kidney failure requiring replacement ...

Please provide your email address to receive an email when new articles are posted on . Overall, 90% of living donors had non-indexed and body surface area indexed mGFR measurements above recommended ...

Chronic kidney disease has long been treated most aggressively when it stems from diabetes, the condition behind a large ...

Research shows many older living kidney donors experience stable long-term kidney health with appropriate risk assessment and follow-up.

A new study found an association between hydroxychloroquine (HCQ) use and early and long-term benefits on kidney function in people with lupus nephritis, (LN, lupus-related kidney disease). HCQ (known ...